Definitions and treatment of oligometastatic oesophagogastric
cancer according to multidisciplinary tumour boards in Europe

J 2022

Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe

KROESE, Tiuri E, Richard VAN HILLEGERSBERG, Sebastian SCHOPPMANN, Pieter R A J DESEYNE, Philippe NAFTEUX et. al.

Basic information

Original name

Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe

Authors

KROESE, Tiuri E, Richard VAN HILLEGERSBERG, Sebastian SCHOPPMANN, Pieter R A J DESEYNE, Philippe NAFTEUX, Radka OBERMANNOVÁ (203 Czech Republic, belonging to the institution), Marianne NORDSMARK, Per PFEIFFER, Maria A HAWKINS, Elizabeth SMYTH, Sheraz MARKAR, George B HANNA, Edward CHEONG, Asif CHAUDRY, Anneli ELME, Antoine ADENIS, Guillaume PIESSEN, Cihan GANI, Christiane J BRUNS, Markus MOEHLER, Theodore LIAKAKOS, John REYNOLDS, Alessio MORGANTI, Riccardo ROSATI, Carlo CASTORO, Domenico UGO, Franco ROVIELLO, Maria BENCIVENGA, de Manzoni GIOVANNI, Paul JEENE, W. VAN SANDICK JOHANNA, Christel MUIJS, Marije SLINGERLAND, Grard NIEUWENHUIJZEN, Bas WIJNHOVEN, Laurens V BEEREPOOT, Piotr KOLODZIEJCZYK, Wojciech P POLKOWSKI, Maria ALSINA, Manuel PERA, Tania F KANONNIKOFF, Magnus NILSSON, Matthias GUCKENBERGER, Stefan MONIG, Dorethea WAGNER, Lucjan WYRWICZ, Maaike BERBEE, Ines GOCKEL, Florian LORDICK, Ewen A GRIFFITHS, Marcel VERHEIJ, S. N. VAN ROSSUM PETER and W. M. VAN LAARHOVEN HANNEKE WM (guarantor)

Edition

European Journal of Cancer, Oxford, Elsevier Science Inc. 2022, 0959-8049

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 8.400

RIV identification code

RIV/00216224:14110/22:00128454

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.ejca.2021.11.032

UT WoS

000792600200002

Keywords in English

Oesophageal neoplasm; Gastric neoplasm; Neoplasm metastasis; Metastasectomy; Radiosurgery; Oligometastasis

Abstract

V originále

Background: Consensus about the definition and treatment of oligometastatic oesophagogastric cancer is lacking. Objective: To assess the definition and treatment of oligometastatic oesophagogastric cancer across multidisciplinary tumour boards (MDTs) in Europe. Material and methods: European expert centers (n Z 49) were requested to discuss 15 real-life cases in their MDT with at least a medical, surgical, and radiation oncologist present. The cases varied in terms of location and number of metastases, histology, timing of detection (i.e. synchronous versus metachronous), primary tumour treatment status, and response to systemic therapy. The primary outcome was the agreement in the definition of oligometastatic disease at diagnosis and after systemic therapy. The secondary outcome was the agreement in treatment strategies. Treatment strategies for oligometastatic disease were categorised into up -front local treatment (i.e. metastasectomy or stereotactic radiotherapy), systemic therapy followed by restaging to consider local treatment or systemic therapy alone. The agreement across MDTs was scored to be either absent/poor (< 50%), fair (50%-75%), or consensus (>= 75%). Results: A total of 47 MDTs across 16 countries fully discussed the cases (96%). Oligometastatic disease was considered in patients with 1-2 metastases in either the liver, lung, retroperitoneal lymph nodes, adrenal gland, soft tissue or bone (consensus). At follow-up, oligometastatic disease was considered after a median of 18 weeks of systemic therapy when no progression or progression in size only of the oligometastatic lesion(s) was seen (consensus). If at restaging after a median of 18 weeks of systemic therapy the number of lesions progressed, this was not considered as oligometastatic disease (fair agreement). There was no consensus on treatment strategies for oligometastatic disease. Conclusion: A broad consensus on definitions of oligometastatic oesophagogastric cancer was found among MDTs of oesophagogastric cancer expert centres in Europe. However, high practice variability in treatment strategies exists.

Citovat

KROESE, Tiuri E, Richard VAN HILLEGERSBERG, Sebastian SCHOPPMANN, Pieter R A J DESEYNE, Philippe NAFTEUX, Radka OBERMANNOVÁ, Marianne NORDSMARK, Per PFEIFFER, Maria A HAWKINS, Elizabeth SMYTH, Sheraz MARKAR, George B HANNA, Edward CHEONG, Asif CHAUDRY, Anneli ELME, Antoine ADENIS, Guillaume PIESSEN, Cihan GANI, Christiane J BRUNS, Markus MOEHLER, Theodore LIAKAKOS, John REYNOLDS, Alessio MORGANTI, Riccardo ROSATI, Carlo CASTORO, Domenico UGO, Franco ROVIELLO, Maria BENCIVENGA, de Manzoni GIOVANNI, Paul JEENE, W. VAN SANDICK JOHANNA, Christel MUIJS, Marije SLINGERLAND, Grard NIEUWENHUIJZEN, Bas WIJNHOVEN, Laurens V BEEREPOOT, Piotr KOLODZIEJCZYK, Wojciech P POLKOWSKI, Maria ALSINA, Manuel PERA, Tania F KANONNIKOFF, Magnus NILSSON, Matthias GUCKENBERGER, Stefan MONIG, Dorethea WAGNER, Lucjan WYRWICZ, Maaike BERBEE, Ines GOCKEL, Florian LORDICK, Ewen A GRIFFITHS, Marcel VERHEIJ, S. N. VAN ROSSUM PETER and W. M. VAN LAARHOVEN HANNEKE WM. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. European Journal of Cancer. Oxford: Elsevier Science Inc., 2022, vol. 164, March 2022, p. 18-29. ISSN 0959-8049. Available from: https://dx.doi.org/10.1016/j.ejca.2021.11.032.

@article{2251523,
   author = {Kroese, Tiuri E and van Hillegersberg, Richard and Schoppmann, Sebastian and Deseyne, Pieter R A J and Nafteux, Philippe and Obermannová, Radka and Nordsmark, Marianne and Pfeiffer, Per and Hawkins, Maria A and Smyth, Elizabeth and Markar, Sheraz and Hanna, George B and Cheong, Edward and Chaudry, Asif and Elme, Anneli and Adenis, Antoine and Piessen, Guillaume and Gani, Cihan and Bruns, Christiane J and Moehler, Markus and Liakakos, Theodore and Reynolds, John and Morganti, Alessio and Rosati, Riccardo and Castoro, Carlo and Ugo, Domenico and Roviello, Franco and Bencivenga, Maria and Giovanni, de Manzoni and Jeene, Paul and van Sandick Johanna, W. and Muijs, Christel and Slingerland, Marije and Nieuwenhuijzen, Grard and Wijnhoven, Bas and Beerepoot, Laurens V and Kolodziejczyk, Piotr and Polkowski, Wojciech P and Alsina, Maria and Pera, Manuel and Kanonnikoff, Tania F and Nilsson, Magnus and Guckenberger, Matthias and Monig, Stefan and Wagner, Dorethea and Wyrwicz, Lucjan and Berbee, Maaike and Gockel, Ines and Lordick, Florian and Griffiths, Ewen A and Verheij, Marcel and van Rossum Peter, S. N. and van Laarhoven Hanneke WM, W. M.},
   article_location = {Oxford},
   article_number = {March 2022},
   doi = {http://dx.doi.org/10.1016/j.ejca.2021.11.032},
   keywords = {Oesophageal neoplasm; Gastric neoplasm; Neoplasm metastasis; Metastasectomy; Radiosurgery; Oligometastasis},
   language = {eng},
   issn = {0959-8049},
   journal = {European Journal of Cancer},
   title = {Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe},
   url = {https://www.sciencedirect.com/science/article/pii/S0959804921012971?via%3Dihub},
   volume = {164},
   year = {2022}
}

TY  - JOUR
ID  - 2251523
AU  - Kroese, Tiuri E - van Hillegersberg, Richard - Schoppmann, Sebastian - Deseyne, Pieter R A J - Nafteux, Philippe - Obermannová, Radka - Nordsmark, Marianne - Pfeiffer, Per - Hawkins, Maria A - Smyth, Elizabeth - Markar, Sheraz - Hanna, George B - Cheong, Edward - Chaudry, Asif - Elme, Anneli - Adenis, Antoine - Piessen, Guillaume - Gani, Cihan - Bruns, Christiane J - Moehler, Markus - Liakakos, Theodore - Reynolds, John - Morganti, Alessio - Rosati, Riccardo - Castoro, Carlo - Ugo, Domenico - Roviello, Franco - Bencivenga, Maria - Giovanni, de Manzoni - Jeene, Paul - van Sandick Johanna, W. - Muijs, Christel - Slingerland, Marije - Nieuwenhuijzen, Grard - Wijnhoven, Bas - Beerepoot, Laurens V - Kolodziejczyk, Piotr - Polkowski, Wojciech P - Alsina, Maria - Pera, Manuel - Kanonnikoff, Tania F - Nilsson, Magnus - Guckenberger, Matthias - Monig, Stefan - Wagner, Dorethea - Wyrwicz, Lucjan - Berbee, Maaike - Gockel, Ines - Lordick, Florian - Griffiths, Ewen A - Verheij, Marcel - van Rossum Peter, S. N. - van Laarhoven Hanneke WM, W. M.
PY  - 2022
TI  - Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe
JF  - European Journal of Cancer
VL  - 164
IS  - March 2022
SP  - 18-29
EP  - 18-29
PB  - Elsevier Science Inc.
SN  - 09598049
KW  - Oesophageal neoplasm
KW  - Gastric neoplasm
KW  - Neoplasm metastasis
KW  - Metastasectomy
KW  - Radiosurgery
KW  - Oligometastasis
UR  - https://www.sciencedirect.com/science/article/pii/S0959804921012971?via%3Dihub
N2  - Background: Consensus about the definition and treatment of oligometastatic oesophagogastric cancer is lacking. Objective: To assess the definition and treatment of oligometastatic oesophagogastric cancer across multidisciplinary tumour boards (MDTs) in Europe. Material and methods: European expert centers (n Z 49) were requested to discuss 15 real-life cases in their MDT with at least a medical, surgical, and radiation oncologist present. The cases varied in terms of location and number of metastases, histology, timing of detection (i.e. synchronous versus metachronous), primary tumour treatment status, and response to systemic therapy. The primary outcome was the agreement in the definition of oligometastatic disease at diagnosis and after systemic therapy. The secondary outcome was the agreement in treatment strategies. Treatment strategies for oligometastatic disease were categorised into up -front local treatment (i.e. metastasectomy or stereotactic radiotherapy), systemic therapy followed by restaging to consider local treatment or systemic therapy alone. The agreement across MDTs was scored to be either absent/poor (< 50%), fair (50%-75%), or consensus (>= 75%). Results: A total of 47 MDTs across 16 countries fully discussed the cases (96%). Oligometastatic disease was considered in patients with 1-2 metastases in either the liver, lung, retroperitoneal lymph nodes, adrenal gland, soft tissue or bone (consensus). At follow-up, oligometastatic disease was considered after a median of 18 weeks of systemic therapy when no progression or progression in size only of the oligometastatic lesion(s) was seen (consensus). If at restaging after a median of 18 weeks of systemic therapy the number of lesions progressed, this was not considered as oligometastatic disease (fair agreement). There was no consensus on treatment strategies for oligometastatic disease. Conclusion: A broad consensus on definitions of oligometastatic oesophagogastric cancer was found among MDTs of oesophagogastric cancer expert centres in Europe. However, high practice variability in treatment strategies exists.
ER  -

KROESE, Tiuri E, Richard VAN HILLEGERSBERG, Sebastian SCHOPPMANN, Pieter R A J DESEYNE, Philippe NAFTEUX, Radka OBERMANNOVÁ, Marianne NORDSMARK, Per PFEIFFER, Maria A HAWKINS, Elizabeth SMYTH, Sheraz MARKAR, George B HANNA, Edward CHEONG, Asif CHAUDRY, Anneli ELME, Antoine ADENIS, Guillaume PIESSEN, Cihan GANI, Christiane J BRUNS, Markus MOEHLER, Theodore LIAKAKOS, John REYNOLDS, Alessio MORGANTI, Riccardo ROSATI, Carlo CASTORO, Domenico UGO, Franco ROVIELLO, Maria BENCIVENGA, de Manzoni GIOVANNI, Paul JEENE, W. VAN SANDICK JOHANNA, Christel MUIJS, Marije SLINGERLAND, Grard NIEUWENHUIJZEN, Bas WIJNHOVEN, Laurens V BEEREPOOT, Piotr KOLODZIEJCZYK, Wojciech P POLKOWSKI, Maria ALSINA, Manuel PERA, Tania F KANONNIKOFF, Magnus NILSSON, Matthias GUCKENBERGER, Stefan MONIG, Dorethea WAGNER, Lucjan WYRWICZ, Maaike BERBEE, Ines GOCKEL, Florian LORDICK, Ewen A GRIFFITHS, Marcel VERHEIJ, S. N. VAN ROSSUM PETER and W. M. VAN LAARHOVEN HANNEKE WM. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. \textit{European Journal of Cancer}. Oxford: Elsevier Science Inc., 2022, vol.~164, March 2022, p.~18-29. ISSN~0959-8049. Available from: https://dx.doi.org/10.1016/j.ejca.2021.11.032.

Detailed Information on Publication Record